Other

University of California

Aphios Corporation

Arthur D Lander

Trevor Percival Castor

Maury D Cosman

Peter Richard d'Entremont

Michael Richard Pelletier

Murray Korc

A wave power generator comprising a chain drive arrangement. The wave power generator comprising a float connected to one end of a retractable chain and a retractable device connected to an opposite end of the retractable chain.

Wave power generator

Glycosylphosphatidylinositol-(GPI-) anchored HSPG glypican-1 is strongly expressed in human breast and pancreatic cancer&#x2014;both by the cancer cells and in the case of pancreatic cancer the adjacent fibroblasts&#x2014;whereas expression of glypican-1 is low in the normal pancreas and in chronic pancreatitis. Treatment of two pancreatic cancer cell lines, which express glypican-1, with the enzyme phosphoinositide-specific phospholipase-C (PI-PLC) abrogated their mitogenic responses to two heparin-binding growth factors: fibroblast growth factor-2 (FGF2) and heparin-binding EGF-like growth factor (HB-EGF). Treatment of MDA-MB-231 and MDA-MB-468 breast cancer cells with PI-PLC abrogates the mitogenic response to two heparin-binding growth factors, heparin-binding epidermal growth factor-like growth factor (HB-EGF) and fibroblast growth factor-2 (FGF-2). Syndecan-1 is also expressed at high levels in breast cancer tissues as well as breast cancer cells by comparison with breast normal tissues. Temporary or permanent transfection of a glypican-1 antisense construct attenuated glypican-1 protein levels and the mitogenic response to FGF2 and HB-EGF. Glypican can be used to detect the carcinoma in vitro and therapeutics that either bind to (e.g., antibodies or drugs), remove (e.g., enzymes) or prevent the expression (e.g., antisense constructs) of surface of the extracellular domain of glypican-1 are effective in retarding the growth of glypican-responsive carcinomas.

Glypican-1 in human breast cancer

The present invention is directed to methods and apparatus for inactivating viruses associated or potentially associated with blood derived samples. The process and apparatus feature critical, supercritical or near critical fluids.

Methods and apparatus for the inactivation of viruses

The invention involves the use of supercritical or near-critical fluids for the inactivation of viruses, especially enveloped or lipid protected viruses, and nonenveloped, protein encased viruses, viral-like particles and other pathogens in any matrix, but preferably in solutions containing biologically active proteinaceous products of natural or genetic engineering origin or in semi-solid or solid support matrices which are thermally labile or sensitive to conventional viral inactivation techniques. Novel apparatus also are provided.

Growing community of inventors

Laguna Beach, CA, United States of America

Arthur D Lander